Supplementary Table S2 from Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers
Year: 2023
Type: supplementary-materials
Abstract: Comparison between percentages of PD-L1 positive tumors using the cut-off at >5% (as in our analysis) and the cut-off >1% (as FDA-approved test for pembrolizumab use in advanced gastric and gastroesophageal junction adenocarcinomas).
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362614044